Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% – What’s Next?

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) dropped 1.7% on Monday . The company traded as low as $4.18 and last traded at $4.08. Approximately 3,152 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 16,604 shares. The stock had previously closed at $4.15.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They set a “buy” rating and a $12.00 price target on the stock.

Eupraxia Pharmaceuticals Price Performance

The firm has a market capitalization of $143.30 million and a PE ratio of -5.58. The business has a 50-day simple moving average of $3.44 and a 200-day simple moving average of $3.08.

Institutional Trading of Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Eupraxia Pharmaceuticals during the fourth quarter worth $31,000. Raymond James Financial Inc. purchased a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth about $37,000. Finally, Bank of Montreal Can grew its holdings in Eupraxia Pharmaceuticals by 15.2% during the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after purchasing an additional 7,500 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.